In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

A multivariate analysis confirmed the independent prognostic significance of both landmark and longitudinal MRD.

A new Yale study has found evidence to support the value of a tool that measures the presence of cancer -derived molecules in ...

Conversely, MRD could also identify patients with low risk of recurrence, possibly sparing them from further treatment and any associated drug toxicities as a result.

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...

In molecular genomics and oncology, Quest Diagnostics progressed with the Haystack MRD blood test for early detection of minimal residual disease (MRD) from solid tumor cancers. Zacks Investment ...

Treatment Blood Test Offers New Hope for Personalized Cancer Therapy DecisionsA new Yale study has found evidence to support ...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...

This tool is a type of molecular residual disease (MRD)detector, which is used after ... the presence of cancer-derived molecules in the blood of patients with lung cancer years after their ...